Stay updated with breaking news from Ontarget Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Click here to access webcast replayCore 2022 development initiatives:Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD)Initiation
Core 2022 development initiatives:Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD)Initiation and completion in 2H 2022
Press release content from Accesswire. The AP news staff was not involved in its creation.
2021 was a year of progress for Jaguar Health as the company advanced its key human pipeline initiatives focused on chemotherapy-related diarrhea (CTD) and short bowel syndrome with intestinal failure